% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rahbar:275256,
      author       = {K. Rahbar and M. Essler and K. M. Pabst$^*$ and M. Eiber
                      and C. l. Fougère and V. Prasad and P. Rassek and E. Hasa
                      and H. Dittmann and R. A. Bundschuh and W. P. Fendler$^*$
                      and M. Kurtinecz and A. Schmall and F. Verholen and O.
                      Sartor},
      title        = {{S}afety and {S}urvival {O}utcomes of
                      177{L}u-{P}rostate-{S}pecific {M}embrane {A}ntigen {T}herapy
                      in {P}atients with {M}etastatic {C}astration-{R}esistant
                      {P}rostate {C}ancer with {P}rior 223{R}a treatment: {T}he
                      {RALU} {S}tudy.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {4},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-00703},
      pages        = {574 - 578},
      year         = {2023},
      abstract     = {The radium lutetium (RALU) study evaluated the feasibility
                      of sequential α- and β-emitter use in patients with
                      bone-predominant metastatic castration-resistant prostate
                      cancer. Methods: This preplanned interim retrospective
                      analysis investigated safety and survival outcomes with
                      177Lu-PSMA in patients treated with prior 223Ra. Results:
                      Forty-nine patients were evaluated. Patients received a
                      median of 6 223Ra injections; $59\%$ of patients received at
                      least 4 177Lu-PSMA cycles. Most $(69\%)$ patients received
                      at least 4 life-prolonging therapies before 177Lu-PSMA.
                      Common Terminology Criteria for Adverse Events grade 3-4
                      treatment-emergent adverse events during 177Lu-PSMA therapy
                      and a 30-d follow-up period included anemia $(18\%)$ and
                      thrombocytopenia $(2\%).$ Median overall survival was 12.6
                      mo $(95\%$ CI, 8.8-16.1 mo) and 31.4 mo $(95\%$ CI,
                      25.7-37.6 mo) from starting 177Lu-PSMA or 223Ra,
                      respectively. Conclusion: 177Lu-PSMA treatment was well
                      tolerated in patients who had received prior 223Ra. 223Ra
                      use before 177Lu-PSMA is feasible and can be considered for
                      future assessment of the optimal treatment sequence.},
      keywords     = {Male / Humans / Lutetium: adverse effects / Radium: adverse
                      effects / Prostatic Neoplasms, Castration-Resistant /
                      Treatment Outcome / Retrospective Studies / Prostate:
                      pathology / Prostate-Specific Antigen / Dipeptides: adverse
                      effects / Heterocyclic Compounds, 1-Ring: adverse effects /
                      177Lu-PSMA (Other) / 223Ra (Other) / metastatic
                      castration-resistant prostate cancer (Other) / real-world
                      practice (Other) / targeted α-therapy (Other) / Lutetium
                      (NLM Chemicals) / Radium (NLM Chemicals) / Prostate-Specific
                      Antigen (NLM Chemicals) / Dipeptides (NLM Chemicals) /
                      Heterocyclic Compounds, 1-Ring (NLM Chemicals)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36302656},
      pmc          = {pmc:PMC10071785},
      doi          = {10.2967/jnumed.122.264456},
      url          = {https://inrepo02.dkfz.de/record/275256},
}